JP2015523332A - 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 - Google Patents

経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 Download PDF

Info

Publication number
JP2015523332A
JP2015523332A JP2015512144A JP2015512144A JP2015523332A JP 2015523332 A JP2015523332 A JP 2015523332A JP 2015512144 A JP2015512144 A JP 2015512144A JP 2015512144 A JP2015512144 A JP 2015512144A JP 2015523332 A JP2015523332 A JP 2015523332A
Authority
JP
Japan
Prior art keywords
nanoparticles
peptide
exendin
metabolic
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512144A
Other languages
English (en)
Japanese (ja)
Inventor
ショーン、マシュー、クリーブランド
マーク、アンドリュー、パウリク
ステファン、サロモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2015523332A publication Critical patent/JP2015523332A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015512144A 2012-05-16 2013-05-16 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 Pending JP2015523332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
US61/647,633 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
JP2015523332A true JP2015523332A (ja) 2015-08-13

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512144A Pending JP2015523332A (ja) 2012-05-16 2013-05-16 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子

Country Status (10)

Country Link
US (1) US20150342897A1 (enExample)
EP (1) EP2849775A1 (enExample)
JP (1) JP2015523332A (enExample)
KR (1) KR20150010953A (enExample)
CN (1) CN104411321A (enExample)
AU (1) AU2013261214A1 (enExample)
CA (1) CA2873536A1 (enExample)
IN (1) IN2014DN09297A (enExample)
RU (1) RU2014150850A (enExample)
WO (1) WO2013171570A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
WO2022132454A1 (en) 2020-12-18 2022-06-23 Spectrum Brands, Inc. Grooming tool for animal and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
CN101896337B (zh) 2007-10-12 2013-10-30 流体科技公司 用于生产颗粒和图案化膜的系统和方法

Also Published As

Publication number Publication date
CA2873536A1 (en) 2013-11-21
CN104411321A (zh) 2015-03-11
RU2014150850A (ru) 2016-07-10
KR20150010953A (ko) 2015-01-29
IN2014DN09297A (enExample) 2015-07-10
AU2013261214A1 (en) 2014-11-20
EP2849775A1 (en) 2015-03-25
WO2013171570A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Gedawy et al. Oral insulin delivery: existing barriers and current counter-strategies
Song et al. Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption
Araujo et al. In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
JP7077237B2 (ja) グルカゴン受容体選択的ポリペプチド及びその使用方法
Seo et al. Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus
Soudry-Kochavi et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
CN104323981B (zh) 基本稳态药物递送的快速建立和/或终止
Momoh et al. Microemulsion-based approach for oral delivery of insulin: formulation design and characterization
US10583080B2 (en) Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2018175250A1 (en) Oral delivery of physiologically active substances
AU2015208699A1 (en) Nanoencapsulation of hydrophilic active compounds
US20150342897A1 (en) Polypeptide loaded poca nanoparticles for oral administration
Pinto et al. Bioengineered nanomedicines targeting the intestinal fc receptor achieve the improved glucoregulatory effect of semaglutide in a type 2 diabetic mice model
Li et al. Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats
CN117545509A (zh) 寡核苷酸的口服递送
CN110623944B (zh) 一种胰高血糖素样肽-1类似物缓释微球制剂及其制备方法
US20210038697A1 (en) Virus-like nanocapsid for oral delivery of insulin
Son et al. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects
M Ramesan et al. Recent advances in the oral delivery of insulin
Raval et al. Nanotechnology Enabled Advances in Oral Delivery of Therapeutic Peptides: Mechanistic Insights for Translation to Clinic
Parida et al. Overcoming hurdles in oral protein and peptide drug delivery: Strategies for future prospective
Raval et al. Nano-biotechnology and its innovative perspective in diabetes management
Okur et al. Current Situation on Diabetes Management: New Weapons Fighting the Disease in 2025
New Oral delivery of biologics via the intestine. Pharmaceutics. 2021; 13: 18
Zhang Development of Peptide and Protein Microparticles for Diabetes Therapy: From Fabrication to In Vivo Evaluation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150203